ArticleFrontiers in microbiology2019
Synergy Between Two Chimeric Lysins to Kill
Article in Frontiers in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- The Oral Virome in Dental Caries: From Ecological Disruptors to Therapeutic Opportunities.Journal of microbiology and biotechnology · 2026Review
- Inhibition of Biofilm Formation by Respiratory Bacterial Pathogens via Silver Nanoparticles and Functionalized HEPA Filters.Antibiotics (Basel, Switzerland) · 2026Article
- Bacteriophages and Their Enzymes: Allies Against Microbial Biofilms.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Recent insights on challenges encountered with phage therapy against gastrointestinal-associated infections.Gut pathogens · 2025Review
- Bacteriophage as a potential biotherapeutics to combat present-day crisis of multi-drug resistant pathogens.Heliyon · 2024Review
- Genetically engineered phages and engineered phage-derived enzymes to destroy biofilms of antibiotics resistance bacteria.Heliyon · 2024Review
- Understanding and treating diabetic foot ulcers: Insights into the role of cutaneous microbiota and innovative therapies.Skin health and disease · 2024Review
- The applications of animal models in phage therapy: An update.Human vaccines & immunotherapeutics · 2023Review
- An Enzybiotic Cocktail Effectively Disrupts Preformed Dual Biofilm ofPharmaceuticals (Basel, Switzerland) · 2023Article
- An Explorative Review on Advanced Approaches to Overcome Bacterial Resistance by Curbing Bacterial Biofilm Formation.Infection and drug resistance · 2023Review
- Improvement of the Antibacterial Activity of Phage Lysin-Derived Peptide P87 through Maximization of Physicochemical Properties and Assessment of Its Therapeutic Potential.Antibiotics (Basel, Switzerland) · 2022Article
- Phages against Pathogenic Bacterial Biofilms and Biofilm-Based Infections: A Review.Pharmaceutics · 2022Review
- Endolysin, a Promising Solution against Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2021Review
- Gram-Positive Pneumonia: Possibilities Offered by Phage Therapy.Antibiotics (Basel, Switzerland) · 2021Review
- Sequence-Function Relationships in Phage-Encoded Bacterial Cell Wall Lytic Enzymes and Their Implications for Phage-Derived Product Design.Journal of virology · 2021Article
- Related Factors to Streptococcus pneumoniae Invasive Infection and Clinical Manifestations: The Potential Role of Nasopharyngeal Microbiome.Frontiers in medicine · 2021Article
- Mining of Gram-Negative Surface-Active Enzybiotic Candidates by Sequence-Based Calculation of Physicochemical Properties.Frontiers in microbiology · 2021Article
- Bacteriophage - A Promising Alternative Measure for Bacterial Biofilm Control.Infection and drug resistance · 2021Review
- A New Phage Lysin Isolated from the Oral Microbiome TargetingPharmaceuticals (Basel, Switzerland) · 2020Article
- Characterization of MSlys, the endolysin ofBiotechnology reports (Amsterdam, Netherlands) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phage lysins constitute a new generation of antimicrobials that are becoming a promising alternative and complementation to current antibiotic therapies, which are nowadays called into question by the increasing numbers of multiresistant bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.